BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 15374529)

  • 21. Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo.
    Ndounga M; Tahar R; Basco LK; Casimiro PN; Malonga DA; Ntoumi F
    Trop Med Int Health; 2007 Oct; 12(10):1164-71. PubMed ID: 17956498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use.
    Nsimba B; Jafari-Guemouri S; Malonga DA; Mouata AM; Kiori J; Louya F; Yocka D; Malanda M; Durand R; Le Bras J
    Trop Med Int Health; 2005 Oct; 10(10):1030-7. PubMed ID: 16185238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity.
    Alifrangis M; Enosse S; Khalil IF; Tarimo DS; Lemnge MM; Thompson R; Bygbjerg IC; Rønn AM
    Am J Trop Med Hyg; 2003 Dec; 69(6):601-6. PubMed ID: 14740875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid selection of dhfr mutant allele in Plasmodium falciparum isolates after the introduction of sulfadoxine/pyrimethamine in combination with 4-aminoquinolines in Papua New Guinea.
    Mita T; Kaneko A; Hwaihwanje I; Tsukahara T; Takahashi N; Osawa H; Tanabe K; Kobayakawa T; Björkman A
    Infect Genet Evol; 2006 Nov; 6(6):447-52. PubMed ID: 16600696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes.
    Méndez F; Herrera S; Murrain B; Gutiérrez A; Moreno LA; Manzano M; Muñoz A; Plowe CV
    Am J Trop Med Hyg; 2007 Sep; 77(3):438-43. PubMed ID: 17827356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria.
    Barnes KI; Little F; Mabuza A; Mngomezulu N; Govere J; Durrheim D; Roper C; Watkins B; White NJ
    J Infect Dis; 2008 Jun; 197(11):1605-13. PubMed ID: 18471066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda.
    Sendagire H; Kyabayinze D; Swedberg G; Kironde F
    Trop Med Int Health; 2005 Jun; 10(6):537-43. PubMed ID: 15941416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania.
    Mbugi EV; Mutayoba BM; Malisa AL; Balthazary ST; Nyambo TB; Mshinda H
    Malar J; 2006 Oct; 5():94. PubMed ID: 17076899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR.
    Toma H; Imada Y; Vannachone B; Miyagi M; Kobayashi J; Uechi G; Pethuvang R; Manivong K; Phompida S; Sato Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):602-4. PubMed ID: 16124424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of sulfadoxine-pyrimethamine resistance-associated mutations in dhfr and dhps genes of Plasmodium falciparum three years after SP withdrawal in Bahir Dar, Northwest Ethiopia.
    Hailemeskel E; Kassa M; Taddesse G; Mohammed H; Woyessa A; Tasew G; Sleshi M; Kebede A; Petros B
    Acta Trop; 2013 Dec; 128(3):636-41. PubMed ID: 24055717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré.
    Bonnet M; Roper C; Félix M; Coulibaly L; Kankolongo GM; Guthmann JP
    Malar J; 2007 May; 6():54. PubMed ID: 17477865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology.
    Alifrangis M; Enosse S; Pearce R; Drakeley C; Roper C; Khalil IF; Nkya WM; Rønn AM; Theander TG; Bygbjerg IC
    Am J Trop Med Hyg; 2005 Feb; 72(2):155-62. PubMed ID: 15741552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania.
    Schönfeld M; Barreto Miranda I; Schunk M; Maduhu I; Maboko L; Hoelscher M; Berens-Riha N; Kitua A; Löscher T
    Malar J; 2007 Jan; 6():2. PubMed ID: 17224049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sulfadoxine-pyrimethamine susceptibilities and analysis of the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum isolates from Côte d'Ivoire.
    Djaman JA; Mazabraud A; Basco L
    Ann Trop Med Parasitol; 2007 Mar; 101(2):103-12. PubMed ID: 17316496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
    Plowe CV; Cortese JF; Djimde A; Nwanyanwu OC; Watkins WM; Winstanley PA; Estrada-Franco JG; Mollinedo RE; Avila JC; Cespedes JL; Carter D; Doumbo OK
    J Infect Dis; 1997 Dec; 176(6):1590-6. PubMed ID: 9395372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from Tanzania.
    Jelinek T; Rønn AM; Lemnge MM; Curtis J; Mhina J; Duraisingh MT; Bygbjerg IC; Warhurst DC
    Trop Med Int Health; 1998 Aug; 3(8):605-9. PubMed ID: 9735930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.
    Kublin JG; Dzinjalamala FK; Kamwendo DD; Malkin EM; Cortese JF; Martino LM; Mukadam RA; Rogerson SJ; Lescano AG; Molyneux ME; Winstanley PA; Chimpeni P; Taylor TE; Plowe CV
    J Infect Dis; 2002 Feb; 185(3):380-8. PubMed ID: 11807721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes.
    Swarthout TD; van den Broek IV; Kayembe G; Montgomery J; Pota H; Roper C
    Trop Med Int Health; 2006 Oct; 11(10):1503-11. PubMed ID: 17002724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?
    Omar SA; Adagu IS; Warhurst DC
    Trans R Soc Trop Med Hyg; 2001; 95(3):315-9. PubMed ID: 11491006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets.
    Alifrangis M; Lemnge MM; Rønn AM; Segeja MD; Magesa SM; Khalil IF; Bygbjerg IC
    Am J Trop Med Hyg; 2003 Sep; 69(3):238-43. PubMed ID: 14628937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.